Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Rosetta Genomics Stories

2013-01-30 12:23:15

PHILADELPHIA and REHOVOT, Israel, Jan. 30, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company will be featured on The Balancing Act(®), a daily morning talk show on the Lifetime(®) Television Network devoted to supporting women. The segment featuring Rosetta Genomics will air on the Lifetime Television Network on February 4(th), February 27th and March 5th from 7:00-8:00...

2013-01-09 08:26:52

PHILADELPHIA and REHOVOT, Israel, Jan. 9, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published in Clinical Experimental Metastasis, in an article entitled "Global microRNA profiling in...

2013-01-04 08:23:16

PHILADELPHIA and REHOVOT, Israel, Jan. 4, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Kenneth A. Berlin, President and CEO, is scheduled to present a corporate overview at Sidoti & Company's 2013 Micro-Cap Conference on Monday, January 7, 2013 at The Grand Hyatt Hotel in New York City. The Rosetta Genomics presentation is scheduled for 9:20 a.m. Eastern Time. The Company's...

2012-11-15 08:32:04

PHILADELPHIA and REHOVOT, Israel, Nov. 15, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced the Company's addition to the Ocean Tomo 300(®) Patent Index ("OT300" or "the Index"), a diversified listing of the 300 companies whose equities trade on major U.S. exchanges that own the most valuable patent portfolios relative to the book value of the company and the only index...

2012-11-08 08:36:01

PHILADELPHIA and REHOVOT, Israel, Nov. 8, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced summoning of a shareholders meeting for the purpose of approving the appointment of Yitzhak Peterburg, M.D., Dr.P.H., MSc. (age 61) to its Board of Directors. Upon approval of this addition by the Company's shareholders, the Company's Board will consist of seven members. Dr. Peterburg is a well-regarded...

2012-11-06 08:29:23

PHILADELPHIA and REHOVOT, Israel, Nov. 6, 2012 /PRNewswire/ -- Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic assays, announces that the New York State Department of Health has given the Company final approval for its miRview(®) lung assay following conditional approval issued in June 2012. With this final approval, Rosetta Genomics can continue to offer the miRview(®) lung assay in all 50 U.S. states. New York is the only...

2012-10-02 02:30:31

PHILADELPHIA, REHOVOT, Israel, and PITTSBURGH, Oct. 2, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, and Precision Therapeutics, Inc. (PTI), a life science company known for its expertise in the science of personalizing cancer therapy by advancing genomic testing and bioinformatics, today announced the commercial launch of the miRview(®) mets(2 )assay in the U.S. oncology market. miRview(®)...

2012-08-29 06:25:32

PHILADELPHIA and REHOVOT, Israel, Aug. 29, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. ("Rosetta") (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced the sale of an additional 825,000 ordinary shares pursuant to the exercise by the underwriter of the over-allotment option granted to the underwriter in connection with Rosetta's recent public offering of 5.5 million ordinary shares at a price to the public of $5.00 per share. The gross...

2012-08-20 02:31:36

PHILADELPHIA and REHOVOT, Israel, Aug. 20, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced the completion of three executive hires and an expansion of its commercial operations in preparation for expected sales growth of its microRNA diagnostic assays, specifically its flagship product miRview(®) mets(2). The Company recently announced a co-marketing agreement with Precision...

2012-08-13 06:24:51

MOUNTAIN VIEW, Calif., Aug. 13, 2012 /PRNewswire/ -- Based on its recent analysis of the next-generation diagnostics market, Frost & Sullivan recognizes Rosetta Genomics with the 2012 North American Frost & Sullivan Award for Entrepreneurial Company of the Year. Rosetta Genomics successfully competes in a concentrated market and achieved significant product adoption, while bringing value to both patients and investors. A recent Frost & Sullivan analysis on the United...